A technology shaped by pandemic-era controversy is finding quieter, more consequential ground in the oncology clinic. Moderna and Merck's positive phase III results in melanoma mark a turning point — not merely for mRNA science, but for how medicine imagines the relationship between a treatment and the singular body it is meant to heal. The promise of a vaccine built not for millions, but for one patient's specific tumor, asks us to reconsider what personalized care can truly mean.